Do residual FVIII levels associated with F8 nonsense mutations reduce the inhibitor risk in hemophilia A patients?

Progetto Bayer Haemophilia Awards Program: Genetic components contributing to the pharmacokinetics of FVIII concentrates

M. Morfini
F. Bernardi

January 2006

Although the heritability of plasma levels of several coagulation factors is high, the underlying mo...

Variation of rs3754689 at lactase gene and inhibitors in admixed Brazilian patients with hemophilia A

L Zuccherato (7706765)
S Eloi-Santos (7706768)
L Jardim (7706771)
R Camelo (7706774)
D Chaves (7706777)
R Souza (7706780)
E Hollox (7706783)
S Rezende (7706786)

March 2019

Hemophilia A is an X-linked bleeding disorder due to mutations in the factor VIII gene (F8). The mos...

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis

F.R. Rosendaal
R. Palla
I. Garagiola
P.M. Mannucci
F. Peyvandi

October 2017

A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), sho...

Hemophilia A patients with nonsense mutations: residual factor VIII expression levels and development of inhibitory antibodies

Alessio Branchini

January 2018

Finanziamento - Progetto finanziato da AICE (Associazione Italiana Centri Emofilia

Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors

A. Coppola
M. Margaglione
E. Santagostino
A. Rocino
E. Grandone
G. Di Minno
AICE PROFIT Study Group
P.M. Mannucci

November 2009

Background: Immune tolerance induction (ITI) is the only therapeutic approach that can eradicate fac...

Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A

De Groot-Eckhardt, C. L.
Van Velzen, A. S.
Peters, Marloes
Peerlinck, K.
Oldenburg, J.
Santagostino, E.
Astermark, J.
Van Heerde, W. L.
Hermans, C.
Morfini, M.
Castaman, G.
Haya, S.
McRae, S.
Reitter-Pfoertner, S. E.
Kamphuisen, P. W.
Van der Bom, J. G.
Fijnvandraat, K. J.

July 2013

Background: The development of neutralizing antibodies (inhibitors) towards factor VIII is a major c...

Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions

Eckhardt, C.
Van Velzen, A.S.
Peters, M.
Streefkerk, N.
Astermark, J.
Oldenburg, J.
Peerlinck, K.
Hay, C.R.M.
Kamphuisen, P.-W.
Santagostino, E.
Van Der Bom, J.G.
Fijnvandraat, K.

July 2011

Introduction: Inhibitor development is a severe complication of mild/ moderate hemophilia A (MHA) an...

Prediction of Factor VIII inhibitor development in the SIPPET cohort by mutational analysis and Factor VIII antigen measurement

S. Spena
I. Garagiola
A. Cannav&#242
M. Mortarino
P.M. Mannucci
F.R. Rosendaal
F. Payvandi
A. El-Beshlawy
M. Elalfy
V. Ramanan
P. Eshghi
S. Hanagavadi
R. Varadarajan
M. Karimi
M.V. Manglani
C. Ross
G. Young
T. Seth
S. Apte
D.M. Nayak
E. Santagostino
M.E. Mancuso
A.C. Sandoval Gonzalez
J.N. Mahlangu
S. Bonanad Boix

April 2018

Background: The type of F8 mutation is the main predictor of inhibitor development in patients with ...

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement

Mortarino, M.
Peyvandi, F.
Cannavo, A.
Mannucci, P. M.
Rosendaal, F. R.
Spena, S.
Garagiola, I.

January 2018

Background: The type of F8 mutation is the main predictor of inhibitor development in patients with ...

Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors

Samuel Sarmiento Doncel
Gina Alejandra Diaz Mosquera
Ronald Guillermo Pelaez
Javier Mauricio Cortes
Carol Agudelo Rico
Francisco Javier Meza Cadavid
Nelson Ramirez Plazas
Ivan Alfredo Perdomo Amar
Jorge Enrique Peña Siado
Fabian Andres Parrado Rey
Cesar Alberto Montaño
Alexys Maza Villadiego

May 2022

Hemophilia A is an X-linked bleeding disorder caused by mutations in the FVIII gene. Genetic factors...

Advances in Hemophilia A Management.

Cho, Sukjoo
Perry, Ashley M
Cheng, Anna M
Wang, Carrie
Rico, Juan Felipe

August 2022

Hemophilia A is an inherited insufficiency of Factor VIII (FVIII), one of the critical clotting fact...

Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: A comprehensive Argentine study of inhibitor risks

Rossetti, Liliana Carmen
Szurkalo, Irupé
Radic, Claudia Pamela
Abelleyro, Miguel Martin
Primiani, Laura
Neme, Daniela
Miguel, Candela
Pérez Bianco, Raúl
De Tezanos Pinto, Miguel
Larripa, Irene Beatriz
de Brasi, Carlos Daniel

July 2013

Inhibitor development against exogenous factor VIII is a severe impairment of replacement therapy af...

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.

Gouw, S.C.
Berg, H.M. van den
Oldenburg, J.
Astermark, J.
Groot, P.G. de
Margaglione, M.
Thompson, A.R.
Heerde, W.L. van
Boekhorst, J.
Miller, C.H.
Cessie, S. le
Bom, J.G. Van Der

January 2012

Item does not contain fulltextThis systematic review was designed to provide more precise effect est...

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Gouw, Samantha C.
van den Berg, H. Marijke
Oldenburg, Johannes
Astermark, Jan
de Groot, Philip G.
Margaglione, Maurizio
Thompson, Arthur R.
van Heerde, Waander
Boekhorst, Jorien
Miller, Connie H.
le Cessie, Saskia
van der Bom, Johanna G.

January 2012

This systematic review was designed to provide more precise effect estimates of inhibitor developmen...

Understanding inhibitor development in haemophilia A: Towards clinical prediction and prevention strategies

Coppola, A
Santoro, Cristina
Tagliaferri, A.
Franchini, M.
Di Minno, G.

January 2010

Inhibitor development, because of its impact on patients' morbidity and quality of life, is presentl...

Progetto Bayer Haemophilia Awards Program: Genetic components contributing to the pharmacokinetics of FVIII concentrates

M. Morfini
F. Bernardi

January 2006

Although the heritability of plasma levels of several coagulation factors is high, the underlying mo...

Variation of rs3754689 at lactase gene and inhibitors in admixed Brazilian patients with hemophilia A

L Zuccherato (7706765)
S Eloi-Santos (7706768)
L Jardim (7706771)
R Camelo (7706774)
D Chaves (7706777)
R Souza (7706780)
E Hollox (7706783)
S Rezende (7706786)

March 2019

Hemophilia A is an X-linked bleeding disorder due to mutations in the factor VIII gene (F8). The mos...

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis

F.R. Rosendaal
R. Palla
I. Garagiola
P.M. Mannucci
F. Peyvandi

October 2017

A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), sho...

Hemophilia A patients with nonsense mutations: residual factor VIII expression levels and development of inhibitory antibodies

Alessio Branchini

January 2018

Finanziamento - Progetto finanziato da AICE (Associazione Italiana Centri Emofilia

Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors

A. Coppola
M. Margaglione
E. Santagostino
A. Rocino
E. Grandone
G. Di Minno
AICE PROFIT Study Group
P.M. Mannucci

November 2009

Background: Immune tolerance induction (ITI) is the only therapeutic approach that can eradicate fac...

Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A

De Groot-Eckhardt, C. L.
Van Velzen, A. S.
Peters, Marloes
Peerlinck, K.
Oldenburg, J.
Santagostino, E.
Astermark, J.
Van Heerde, W. L.
Hermans, C.
Morfini, M.
Castaman, G.
Haya, S.
McRae, S.
Reitter-Pfoertner, S. E.
Kamphuisen, P. W.
Van der Bom, J. G.
Fijnvandraat, K. J.

July 2013

Background: The development of neutralizing antibodies (inhibitors) towards factor VIII is a major c...

Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions

Eckhardt, C.
Van Velzen, A.S.
Peters, M.
Streefkerk, N.
Astermark, J.
Oldenburg, J.
Peerlinck, K.
Hay, C.R.M.
Kamphuisen, P.-W.
Santagostino, E.
Van Der Bom, J.G.
Fijnvandraat, K.

July 2011

Introduction: Inhibitor development is a severe complication of mild/ moderate hemophilia A (MHA) an...

Prediction of Factor VIII inhibitor development in the SIPPET cohort by mutational analysis and Factor VIII antigen measurement

S. Spena
I. Garagiola
A. Cannav&#242
M. Mortarino
P.M. Mannucci
F.R. Rosendaal
F. Payvandi
A. El-Beshlawy
M. Elalfy
V. Ramanan
P. Eshghi
S. Hanagavadi
R. Varadarajan
M. Karimi
M.V. Manglani
C. Ross
G. Young
T. Seth
S. Apte
D.M. Nayak
E. Santagostino
M.E. Mancuso
A.C. Sandoval Gonzalez
J.N. Mahlangu
S. Bonanad Boix

April 2018

Background: The type of F8 mutation is the main predictor of inhibitor development in patients with ...

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement

Mortarino, M.
Peyvandi, F.
Cannavo, A.
Mannucci, P. M.
Rosendaal, F. R.
Spena, S.
Garagiola, I.

January 2018

Background: The type of F8 mutation is the main predictor of inhibitor development in patients with ...

Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors

Samuel Sarmiento Doncel
Gina Alejandra Diaz Mosquera
Ronald Guillermo Pelaez
Javier Mauricio Cortes
Carol Agudelo Rico
Francisco Javier Meza Cadavid
Nelson Ramirez Plazas
Ivan Alfredo Perdomo Amar
Jorge Enrique Peña Siado
Fabian Andres Parrado Rey
Cesar Alberto Montaño
Alexys Maza Villadiego

May 2022

Hemophilia A is an X-linked bleeding disorder caused by mutations in the FVIII gene. Genetic factors...

Advances in Hemophilia A Management.

Cho, Sukjoo
Perry, Ashley M
Cheng, Anna M
Wang, Carrie
Rico, Juan Felipe

August 2022

Hemophilia A is an inherited insufficiency of Factor VIII (FVIII), one of the critical clotting fact...

Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: A comprehensive Argentine study of inhibitor risks

Rossetti, Liliana Carmen
Szurkalo, Irupé
Radic, Claudia Pamela
Abelleyro, Miguel Martin
Primiani, Laura
Neme, Daniela
Miguel, Candela
Pérez Bianco, Raúl
De Tezanos Pinto, Miguel
Larripa, Irene Beatriz
de Brasi, Carlos Daniel

July 2013

Inhibitor development against exogenous factor VIII is a severe impairment of replacement therapy af...

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.

Gouw, S.C.
Berg, H.M. van den
Oldenburg, J.
Astermark, J.
Groot, P.G. de
Margaglione, M.
Thompson, A.R.
Heerde, W.L. van
Boekhorst, J.
Miller, C.H.
Cessie, S. le
Bom, J.G. Van Der

January 2012

Item does not contain fulltextThis systematic review was designed to provide more precise effect est...

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Gouw, Samantha C.
van den Berg, H. Marijke
Oldenburg, Johannes
Astermark, Jan
de Groot, Philip G.
Margaglione, Maurizio
Thompson, Arthur R.
van Heerde, Waander
Boekhorst, Jorien
Miller, Connie H.
le Cessie, Saskia
van der Bom, Johanna G.

January 2012

This systematic review was designed to provide more precise effect estimates of inhibitor developmen...

Understanding inhibitor development in haemophilia A: Towards clinical prediction and prevention strategies

Coppola, A
Santoro, Cristina
Tagliaferri, A.
Franchini, M.
Di Minno, G.

January 2010

Inhibitor development, because of its impact on patients' morbidity and quality of life, is presentl...

Progetto Bayer Haemophilia Awards Program: Genetic components contributing to the pharmacokinetics of FVIII concentrates

M. Morfini
F. Bernardi

January 2006

Although the heritability of plasma levels of several coagulation factors is high, the underlying mo...

Variation of rs3754689 at lactase gene and inhibitors in admixed Brazilian patients with hemophilia A

L Zuccherato (7706765)
S Eloi-Santos (7706768)
L Jardim (7706771)
R Camelo (7706774)
D Chaves (7706777)
R Souza (7706780)
E Hollox (7706783)
S Rezende (7706786)

March 2019

Hemophilia A is an X-linked bleeding disorder due to mutations in the factor VIII gene (F8). The mos...

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis

F.R. Rosendaal
R. Palla
I. Garagiola
P.M. Mannucci
F. Peyvandi

October 2017

A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), sho...

Do residual FVIII levels associated with F8 nonsense mutations reduce the inhibitor risk in hemophilia A patients?

Abstract

Extracted data

Do residual FVIII levels associated with F8 nonsense mutations reduce the inhibitor risk in hemophilia A patients?

Abstract

Extracted data

Related items

Related items